CTLA4 and gastric cancer: Last but not least, the TISMO data demonstrated that the differential expression of GDF3, 6, and 11 in GC may contribute to the anti-CTLA4 (not anti-PD1) immunotherapy of GC which may require further validation in large patients’ immunotherapy data (Fig. 6E and F).